DSGN · Nasdaq · ·
Next earnings: November 4, 2026
$12.64+2.2%Sep 29 close
Design Therapeutics, Inc. is scheduled to report next on November 4, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | — |
| Profit | -$20.2M | -$19.1M | -5.67% |
| Profit per share | -$0.32 | -$0.34 | +5.88% |
| Free Cash Flow | -$15.5M | -$14.5M | -7.00% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Design continued its strong operational execution in the second quarter building on the positive RESTORE-FA data reported in May. Those four-week data demonstrated the ability of DT-216P2 to increase endogenous frataxin and its potential to deliver a differentiated, best-in-disease therapy for Friedreich ataxia,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC ® gene targeted chimera small molecules. The company’s GeneTAC ® molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its clinical-stage GeneTAC ® programs, DT-216P2, in development for patients with Friedreich ataxia, DT-168, for Fuchs endothelial corneal dystrophy, and DT-818, for myotonic dystrophy type-1, the company is advancing a program in Huntington’s disease. Discovery efforts are underway for multiple genomic medicines.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Design Therapeutics, Inc.’s Item 2.02 8-K filed August 3, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Design Therapeutics, Inc. has no earnings call transcript available.